Ares Financial Consulting
DGX icon

Ares Financial Consulting’s Quest Diagnostics DGX Stock Holding History

Ares Financial Consulting’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.86K Hold
38
– – 0.01% 582
2026
Q2 		$8.05K Hold
38
– – 0.01% 613
2026
Q1 		$7.51K Hold
38
– – 0.01% 608
2025
Q4 		$6.59K Buy
+38
New +$6.92K 0.01% 423

Other funds holding DGX

Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Davis Selected Advisers
Davis Selected Advisers Tucson, Arizona $23.2B AUM 18.42% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
M&G plc
M&G plc London, United Kingdom $19.9B AUM 15.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Ares Financial Consulting's DGX Position: Q3 2026 in Review

Ares Financial Consulting held its Quest Diagnostics (DGX) position steady in Q3 2026 at 38 shares worth $8.86K. The position accounts for 0.01% of the portfolio, ranked #582.

Ares Financial Consulting first reported a position in DGX in Q4 2025 and has held it in 4 quarters since. 722 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Ares Financial Consulting held 38 shares of Quest Diagnostics worth $8.86K as of Q3 2026.
  • Ares Financial Consulting left its Quest Diagnostics share count unchanged in Q3 2026.
  • Quest Diagnostics made up 0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #582 holding.
  • Ares Financial Consulting first reported a position in Quest Diagnostics in Q4 2025 and has held it in 4 quarters since.
  • 722 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.